• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals.沙特阿拉伯特发性肺纤维化:来自两家三级护理医院的人口统计学、临床和生存数据。
Ann Thorac Med. 2014 Jul;9(3):168-72. doi: 10.4103/1817-1737.134073.
2
Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis.中东地区特发性肺纤维化患者的临床及功能转归
Clin Respir J. 2008 Oct;2(4):220-6. doi: 10.1111/j.1752-699X.2008.00070.x.
3
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.特发性肺纤维化合并轻度生理损害的疾病进展:来自澳大利亚特发性肺纤维化登记处的分析。
BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.
4
Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.特发性间质性肺炎未分类急性加重:与特发性肺纤维化的比较。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935774. doi: 10.1177/1753466620935774.
5
Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.特发性肺纤维化初始评估中肺动脉高压作为预后指标。
Respiration. 2013;85(6):456-63. doi: 10.1159/000345221. Epub 2012 Dec 19.
6
[Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].[抗合成酶综合征相关间质性肺病和特发性肺纤维化中肺功能检查及KL-6的特征与临床意义]
Zhonghua Yi Xue Za Zhi. 2020 Mar 17;100(10):748-752. doi: 10.3760/cma.j.cn112137-20191008-02166.
7
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.在特发性肺纤维化前瞻性结局(IPF-PRO)注册研究中,特发性肺纤维化患者的基于医院的资源利用和费用。
Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
8
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.重组人 Pentraxin 2 与安慰剂对特发性肺纤维化患者用力肺活量变化的影响:一项随机临床试验。
JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.
9
Pulmonary hypertension in chronic lung diseases.慢性肺部疾病相关肺动脉高压。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
10
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.

引用本文的文献

1
The most common pulmonary diseases length of stay, and characteristics of patients admitted to pulmonary service.肺部疾病患者入住肺部科室的最常见住院时长及特征。
Ann Thorac Med. 2023 Jul-Sep;18(3):124-131. doi: 10.4103/atm.atm_348_22. Epub 2023 Jul 19.
2
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.特发性肺纤维化患者未接受抗纤维化治疗的预后:一项系统评价。
Eur Respir Rev. 2020 Aug 4;29(157). doi: 10.1183/16000617.0158-2019. Print 2020 Sep 30.
3
Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis.糖尿病与特发性肺纤维化的关系:从临床表型到可能发病机制的综述。
Front Public Health. 2020 Jun 3;8:196. doi: 10.3389/fpubh.2020.00196. eCollection 2020.
4
Metabolic Disorders in Chronic Lung Diseases.慢性肺病中的代谢紊乱
Front Med (Lausanne). 2018 Jan 18;4:246. doi: 10.3389/fmed.2017.00246. eCollection 2017.

本文引用的文献

1
Interstitial lung diseases in Saudi Arabia: A single-center study.沙特阿拉伯的间质性肺疾病:一项单中心研究。
Ann Thorac Med. 2013 Jan;8(1):33-7. doi: 10.4103/1817-1737.105717.
2
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.特发性肺纤维化的发病率和患病率:文献复习。
Eur Respir Rev. 2012 Dec 1;21(126):355-61. doi: 10.1183/09059180.00002512.
3
Baseline values and short serial change: a "road map" for a poor early outcome in idiopathic pulmonary fibrosis.基线值与短期连续变化:特发性肺纤维化早期预后不良的“路线图”
Am J Respir Crit Care Med. 2011 Aug 15;184(4):395-7. doi: 10.1164/rccm.201107-1216ED.
4
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.胃食管反流治疗与特发性肺纤维化患者的生存时间延长有关。
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1390-4. doi: 10.1164/rccm.201101-0138OC. Epub 2011 Jun 23.
5
The rising incidence of idiopathic pulmonary fibrosis in the U.K.英国特发性肺纤维化发病率的上升
Thorax. 2011 Jun;66(6):462-7. doi: 10.1136/thx.2010.148031. Epub 2011 Apr 27.
6
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.特发性肺纤维化:诊断和管理的循证指南(美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布)
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
7
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.特发性肺纤维化的临床病程和生存预测。
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8.
8
Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis.中东地区特发性肺纤维化患者的临床及功能转归
Clin Respir J. 2008 Oct;2(4):220-6. doi: 10.1111/j.1752-699X.2008.00070.x.
9
Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis.特发性肺纤维化患者中心血管疾病的患病率和影响。
Respir Med. 2010 Jul;104(7):1035-41. doi: 10.1016/j.rmed.2010.02.008. Epub 2010 Mar 2.
10
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.特发性肺纤维化患者的 6 分钟步行试验:纵向变化和最小临床重要差异。
Thorax. 2010 Feb;65(2):173-7. doi: 10.1136/thx.2009.113498. Epub 2009 Dec 8.

沙特阿拉伯特发性肺纤维化:来自两家三级护理医院的人口统计学、临床和生存数据。

Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals.

机构信息

King Fahad Hospital, Madinah, Kingdom of Saudi Arabia.

King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.

出版信息

Ann Thorac Med. 2014 Jul;9(3):168-72. doi: 10.4103/1817-1737.134073.

DOI:10.4103/1817-1737.134073
PMID:24987477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4073575/
Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is rare and can be challenging to diagnose. Limited data is available from the Middle Eastern region, especially Saudi Arabia.

METHODS

This was a retrospective study that looked at all the patients diagnosed with IPF between 2007 and 2012 at two tertiary care hospitals in Saudi Arabia. We collected the demographical, clinical, laboratory and radiological data from the patients' medical records. Medications administered and 1 year survival was also assessed.

RESULTS

Between 2007and 2012, 134 IPF patients were identified. Their baseline characteristics (Mean ± SD) included: age 64 ± 13 years, body mass index 29 ± 8 kg/m(2), FEV1 56 ± 15 percent of predicted, FVC 53 ± 13 percent of predicted, FEV1/FVC 0.81 ± 0.09, total lung capacity 75 ± 13 percent of predicted, diffusing capacity of the lung for carbon monoxide 57 ± 15 percent of predicted, on home oxygen at presentation 71 (53%), mean ejection fraction 0.50 ± 0.07, mean pulmonary artery systolic pressure (via echocardiogram) 40 + 22 mmHg, presentation mean SpO292 ± 7%, presentation 6-min walk distance 338 ± 64 m and lowest SpO2 during 6-min walk test 88 ± 5%. Patients were predominantly female (56%), and 42% of patients had diabetes and were active smokers. The IPF patients' frequency of hospital admission (n = 99) was 2.4 ± 1.7 per year and duration of hospital stay (n = 99) was 17.4 ± 23.8 days. Overall 1 year survival in all IPF patients was good, 93% (124) patients remained alive after 1 year.

CONCLUSIONS

In Saudi Arabia, IPF patients tended to be slightly older and the disease progression was somewhat slower than reported IPF cohorts in other populations. They had frequent hospital admissions and a long hospital length of stay. The influence of genetics and co-morbid diseases on the incidence and outcome of IPF should be explored further.

摘要

背景

特发性肺纤维化(IPF)较为罕见,诊断具有一定难度。目前,有关中东地区,尤其是沙特阿拉伯的相关数据十分有限。

方法

这是一项回顾性研究,研究对象为 2007 年至 2012 年期间在沙特阿拉伯两家三级保健医院确诊为 IPF 的所有患者。我们从患者的病历中收集人口统计学、临床、实验室和影像学数据。同时评估患者的用药情况和 1 年生存率。

结果

2007 年至 2012 年期间,共确定了 134 例 IPF 患者。其基线特征(平均值±标准差)包括:年龄 64±13 岁,体重指数 29±8kg/m2,FEV1 占预计值的 56±15%,FVC 占预计值的 53±13%,FEV1/FVC 为 0.81±0.09,总肺容量占预计值的 75±13%,一氧化碳弥散量占预计值的 57±15%,就诊时家中吸氧 71 例(53%),平均射血分数 0.50±0.07,平均肺动脉收缩压(经超声心动图)40+22mmHg,就诊时平均 SpO292±7%,就诊时 6 分钟步行距离 338±64m,6 分钟步行试验时最低 SpO2 为 88±5%。患者以女性为主(56%),42%的患者患有糖尿病且为吸烟人群。IPF 患者的住院频率(n=99)为每年 2.4±1.7 次,住院时间(n=99)为 17.4±23.8 天。所有 IPF 患者的 1 年生存率良好,93%(124 例)患者在 1 年后仍存活。

结论

在沙特阿拉伯,IPF 患者的年龄略大,疾病进展速度比其他人群报道的 IPF 队列稍慢。他们经常住院,住院时间长。遗传因素和合并症对 IPF 的发病率和结局的影响需要进一步探讨。